Satoshi Kobayashi

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Dai Inoue · 2 shared papers, 2018–2026 · strength 0.39
   • Paper Malignant potential of intraductal papillary mucinous neoplasm (IPMN) of the pancreas: imaging assessment of IPMN-deriv… DOI 10.1007/s11604-026-02067-6↗
   • Paper Qualitative and quantitative evaluation for morphological changes of the splenic artery in autoimmune pancreatitis: nov… DOI 10.1007/s00261-018-1634-9↗
2. Fumihito Toshima · 2 shared papers, 2018–2026 · strength 0.39
   • Paper Malignant potential of intraductal papillary mucinous neoplasm (IPMN) of the pancreas: imaging assessment of IPMN-deriv… DOI 10.1007/s11604-026-02067-6↗
   • Paper Qualitative and quantitative evaluation for morphological changes of the splenic artery in autoimmune pancreatitis: nov… DOI 10.1007/s00261-018-1634-9↗
3. Shuichi Mitsunaga · 1 shared paper, 2025 · strength 0.19
   • Paper Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treat… DOI 10.1016/j.ejca.2025.115424↗
4. Yoshito Komatsu · 1 shared paper, 2025 · strength 0.19
   • Paper Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treat… DOI 10.1016/j.ejca.2025.115424↗
5. Taro Yamashita · 1 shared paper, 2025 · strength 0.19
   • Paper Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treat… DOI 10.1016/j.ejca.2025.115424↗
6. Mitsuhito Sasaki · 1 shared paper, 2025 · strength 0.19
   • Paper Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treat… DOI 10.1016/j.ejca.2025.115424↗
7. Masafumi Ikeda · 1 shared paper, 2025 · strength 0.19
   • Paper Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treat… DOI 10.1016/j.ejca.2025.115424↗
8. Naohiro Okano · 1 shared paper, 2025 · strength 0.19
   • Paper Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treat… DOI 10.1016/j.ejca.2025.115424↗
9. Masato Ozaka · 1 shared paper, 2025 · strength 0.19
   • Paper Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treat… DOI 10.1016/j.ejca.2025.115424↗
10. Hiroaki Nagano · 1 shared paper, 2025 · strength 0.19
    • Paper Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treat… DOI 10.1016/j.ejca.2025.115424↗
11. Takaaki Furukawa · 1 shared paper, 2025 · strength 0.19
    • Paper Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treat… DOI 10.1016/j.ejca.2025.115424↗
12. Hiroshi Imaoka · 1 shared paper, 2025 · strength 0.19
    • Paper Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treat… DOI 10.1016/j.ejca.2025.115424↗
13. Junji Furuse · 1 shared paper, 2025 · strength 0.19
    • Paper Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treat… DOI 10.1016/j.ejca.2025.115424↗
14. Makoto Ueno · 1 shared paper, 2025 · strength 0.19
    • Paper Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treat… DOI 10.1016/j.ejca.2025.115424↗
15. Toshifumi Gabata · 1 shared paper, 2018 · strength 0.08
    • Paper Qualitative and quantitative evaluation for morphological changes of the splenic artery in autoimmune pancreatitis: nov… DOI 10.1007/s00261-018-1634-9↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.